keyword
https://read.qxmd.com/read/38554983/development-of-novel-pyrimidine-nucleoside-analogs-as-potential-anticancer-agents-synthesis-characterization-and-in-vitro-evaluation-against-pancreatic-cancer
#21
JOURNAL ARTICLE
Esther Frimpong, Raviteja Bulusu, Joy Okoro, Andriana Inkoom, Nkafu Ndemazie, Sherise Rogers, Xue Zhu, Bo Han, Edward Agyare
The present study proposed modification of 5-FU by conjugation with an acyl chloride and a 5-membered heterocyclic ring to improve its in-vitro cytotoxicity and metabolic stability. XYZ-I-71 and XYZ-I-73 were synthesized by introducing a tetrahydrofuran ring on 5-fluorocytosine (a precursor of 5-FU) and conjugation with octanoyl chloride and lauroyl chloride, respectively. The structure of the synthesized compounds was validated using NMR and micro-elemental analysis. The antiproliferative activity of the analogs was determined against MiaPaCa-2, PANC-1, and BxPC-3 pancreatic cancer cells...
March 28, 2024: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38554475/design-synthesis-and-biological-evaluation-of-matrine-contains-benzimidazole-derivatives-as-dual-topoi-and-parp-inhibitors-for-cancer-therapy
#22
JOURNAL ARTICLE
Gan Qiu, Junwei Xie, Fan Li, Keyan Han, Qingfeng Long, Jamal A H Kowah, Ruobing Gao, Lisheng Wang, Xu Liu
TOPOI inhibitors have long been a focal point in the research and development of antitumor drugs. PARP-1 plays a crucial role in repairing DNA damage induced by TOPOI inhibitors. Thus, concurrent inhibition of TOPOI and PARP-1 has the potential to augment drug activity. Matrine, characterized by low toxicity and good water solubility, offers advantageous properties. In this investigation, a series of benzimidazole matrine derivatives were designed and synthesized using matrine as the lead compound with the aim of developing dual inhibitors targeting both TOPOI and PARP-1...
March 27, 2024: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/38554381/furanocoumarin-compounds-isolated-from-dorstenia-foetida-potentiate-irinotecan-anticancer-activity-against-colorectal-cancer-cells
#23
JOURNAL ARTICLE
Supusson Pengnam, Watcharapa Jitkaroon, Roongtiwa Srisuphan, Pawaris Wongprayoon, Kanok-On Rayanil, Purin Charoensuksai
Although the anticancer activity of Dorstenia foetida was already observed, the chemical entity responsible for this activity remained unidentified. In this study, the cytotoxic activity of two furanocoumarin compounds, i . e ., 5-methoxy--3-(3-methyl-2,3-dihydroxybutyl)-psoralen ( 1 ) and 5-methoxy-3-(3-methyl-2,3-dihydroxybutyl)-psoralen diacetate ( 2 ) isolated from ethyl acetate fraction of D. foetida (whole plant) was investigated in several cancer cell lines including HN22, MDA-MB-231, HCT116, and HT29...
March 1, 2024: Acta Pharmaceutica
https://read.qxmd.com/read/38554321/modified-folfirinox-mfolfirinox-as-neoadjuvant-therapy-and-salvage-in-patients-with-high-risk-locally-advanced-rectal-cancers-tolerance-and-early-outcomes
#24
JOURNAL ARTICLE
Ramjas Prajapati, Vikas Ostwal, Sujay Srinivas, Reena Engineer, Prabhat Bhargava, Avanish Saklani, Ashwin D'Souza, Suman Kumar, Zoya Peelay, P Manali, Anant Ramaswamy
BACKGROUND: There is limited data with regard to the use of modified 5-fluoroural-leucovorin-irinotecan-oxaliplatin (mFOLFIRINOX) in terms of tolerance and enabling total mesorectal excision (TME) of locally advanced rectal adenocarcinomas (LARC) with high-risk characteristics (T4b status, signet ring histology etc) post standard neoadjuvant long course chemoradiation (NACTRT) or short course radiation (SCRT) and chemotherapy. MATERIALS AND METHODS: Patients with LARC from January 2018 to December 2020 receiving mFOLFIRINOX post NACTRT/SCRT to facilitate TME were evaluated...
January 1, 2024: Journal of Cancer Research and Therapeutics
https://read.qxmd.com/read/38553260/a-real-world-analysis-of-second-line-treatment-option-gemcitabine-plus-anlotinib-and-anti-pd1-in-advanced-pancreatic-cancer
#25
JOURNAL ARTICLE
Mengjiao Fan, Yue Ma, Guochao Deng, Haiyan Si, Ru Jia, Zhikuan Wang, Guanghai Dai
BACKGROUND: In the second-line treatment of advanced pancreatic cancer (APC), there is only one approved regimen based on the phase III NAPOLI-1 trial. However, for patients progressing after Nab-paclitaxel and Gemcitabine (Nab-P/Gem) or Nab-P combinations, second-line treatment were very limited. METHODS: This is a retrospective single-center analysis of patients. Our aim was to determine the effectiveness and tolerability of a novel regimen, gemcitabine plus Anlotinib and anti-PD1, in APC patients and to compare it with oxaliplatin, irinotecan, leucovorin, and fluorouracil (FOLFIRINOX) in the second-line setting who have failed on the first-line Nab-P combinations...
March 25, 2024: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://read.qxmd.com/read/38553252/prognostic-factors-for-overall-survival-and-safety-of-trans-arterial-chemoembolization-tace-with-irinotecan-loaded-drug-eluting-beads-debiri-in-patients-with-colorectal-liver-metastases
#26
JOURNAL ARTICLE
Maja Sljivic, Masa Sever, Janja Ocvirk, Tanja Mesti, Erik Brecelj, Peter Popovic
BACKGROUND: Transarterial chemoembolisation with irinotecan-loaded drug-eluting beads (DEBIRI TACE) can be considered in patients with unresectable colorectal cancer liver metastases (CRLM) who progress after all approved standard therapies or in patients unsuitable for systemic therapy. PATIENTS AND METHODS: Between September 2010 and March 2020, thirty patients (22 men and 8 women; mean age 66.8 ± 13.2) were included in this retrospective study. DEBIRI TACE was conducted in 43% of patients unsuitable for systemic therapy as a first-line treatment and 57% as salvage therapy after the progression of systemic therapy...
March 30, 2024: Radiology and Oncology
https://read.qxmd.com/read/38549624/an-improvement-of-exertional-dyspnea-by-the-reintroduction-of-anti-egfr-antibody-in-patients-with-metastatic-rectal-cancer-who-developed-cancerous-lymphangiopathy-a-case-report
#27
Masatsune Shibutani, Hideki Tanda, Tatsunari Fukuoka, Hiroaki Kasashima, Shinichiro Kashiwagi, Kiyoshi Maeda
INTRODUCTION: Reexposure to anti-EGFR antibodies, such as a reintroduction or rechallenge with anti-EGFR antibodies, has attracted much attention in the field of metastatic colorectal cancer. A reintroduction of anti-EGFR antibodies often shows good therapeutic outcomes, as most patients eligible for such reintroduction discontinued treatment due to adverse events despite a good treatment response during front-line treatment. We herein report a case demonstrating an improvement in exertional dyspnea after the reintroduction of anti-EGFR antibody in a patient with metastatic rectal cancer who developed cancerous lymphangiopathy...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38549003/prognosis-of-a-heterogeneous-trg-pathological-response-to-neoadjuvant-chemotherapy-in-patients-who-undergo-resection-for-colorectal-liver-metastases
#28
REVIEW
Sophie Laroche, Olivier Scatton, Frederic Charlotte, Jean-Baptiste Bachet, Chetana Lim, David Fuks, Claire Goumard
BACKGROUND: Optimal management of colorectal liver metastasis (CRLM) is based on a combination of chemotherapy and surgical resection. The tumor regression grade (TRG) score is a histological scoring system to evaluate response to chemotherapy. The prognosis of a heterogeneous response in cases of multiple metastases has not been evaluated according to the TRG score. PATIENTS AND METHODS: All patients who underwent liver resection for multiple CRLM after neoadjuvant chemotherapy in two tertiary centers from January 2015 to April 2019 were retrospectively included...
March 28, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38543173/sulfarotene-inhibits-colorectal-cancer-via-mitigating-natural-killer-cell-induced-stemness
#29
JOURNAL ARTICLE
Keshu Hu, Yu Dong, Jiayu Zhang, Mengling Liu, Xun Sun, Xin Cao, Pengfei Zhang, Tianshu Liu
Tumor cell stemness stands out as a pivotal factor driving tumor recurrence or metastasis and significantly contributes to the mortality of patients with colorectal cancer (CRC). Recent research has unveiled a link between immune-active cells and the induction of tumor cell stemness, ultimately leading to heightened resistance to treatment. In this study, stemness in CRC cell lines was assessed after co-culture with natural killer (NK) cells, both with and without sulfarotene administration. Furthermore, a CRC xenograft model was utilized to scrutinize the in vivo efficacy of sulfarotene in overcoming stemness induced by NK cell activation...
March 18, 2024: Pharmaceuticals
https://read.qxmd.com/read/38538002/reduction-of-tumor-biomarkers-from-very-high-to-normal-and-extensive-metastatic-lesions-to-undetectability-in-a-patient-with-stage-iv-her2-positive-breast-cancer-treated-with-low-dose-trastuzumab-deruxtecan-in-combination-with-oral-recombinant-methioninase
#30
JOURNAL ARTICLE
Motokazu Sato, Qinghong Han, Ryosuke Mori, Kohei Mizuta, Byung Mo Kang, Sei Morinaga, Noritoshi Kobayashi, Yasushi Ichikawa, Atsushi Nakajima, Robert M Hoffman
BACKGROUND/AIM: Breast cancer is the most common and the deadliest cancer among women in the world. Treatment options for HER2-positive metastatic breast cancer patients are limited. Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate (ADC), has recently been introduced as second-line chemotherapy for HER2-positive metastatic breast cancer. The aim of the present study was to evaluate the efficacy of methionine restriction with oral recombinant methioninase (o-rMETase) and a low-methionine diet combined with T-DXd, on a patient with HER2-positive recurrent stage IV breast cancer...
April 2024: Anticancer Research
https://read.qxmd.com/read/38534052/multispecialty-management-of-metastatic-colon-adenocarcinoma-involving-the-extraocular-muscles-primary-excision-and-simultaneous-treatment-of-strabismus-with-a-review-of-the-literature
#31
JOURNAL ARTICLE
Fereshteh Azad, Tassapol Singalavanija, Robert Beaulieu, Federica Mingardo, Steven M Archer, Victor Maurice Elner, Hakan Demirci
Metastatic colon adenocarcinoma involving the extraocular muscles is extremely rare. It usually develops following the diagnosis of the systemic disease and therefore, management and treatment require a multispecialty approach. Within this manuscript, we provide a summary of cases of orbital metastasis secondary to colon cancer. We further discuss a detailed case of a 42-year-old male patient who developed recent-onset diplopia in the left gaze. Orbital CT imaging showed a localized, well-circumscribed enlargement of the right medial rectus muscle...
March 21, 2024: Ophthalmic Plastic and Reconstructive Surgery
https://read.qxmd.com/read/38533822/vascularized-tissue-on-mesh-assisted-platform-vt-map-a-novel-approach-for-diverse-organoid-size-culture-and-tailored-cancer-drug-response-analysis
#32
JOURNAL ARTICLE
Jungseub Lee, Sangmin Jung, Hye Kyoung Hong, Hyeonsu Jo, Stephen Rhee, Ye-Lin Jeong, Jihoon Ko, Yong Beom Cho, Noo Li Jeon
This study presents the vascularized tissue on mesh-assisted platform (VT-MAP), a novel microfluidic in vitro model that uses an open microfluidic principle for cultivating vascularized organoids. Addressing the gap in 3D high-throughput platforms for drug response analysis, the VT-MAP can host tumor clusters of various sizes, allowing for precise, size-dependent drug interaction assessments. Key features include capability for forming versatile co-culture conditions (EC, fibroblasts and colon cancer organoids) that enhance tumor organoid viability and a perfusable vessel network that ensures efficient drug delivery and maintenance of organoid health...
March 27, 2024: Lab on a Chip
https://read.qxmd.com/read/38530942/important-radiologic-and-clinical-factors-for-predicting-overall-survival-in-pancreatic-adenocarcinoma-patients-who-underwent-folfirinox
#33
JOURNAL ARTICLE
Sae-Jin Park, Jung Hoon Kim, Seo-Youn Choi, Ijin Joo
BACKGROUND: To predict poor overall survival (OS) in pancreatic adenocarcinoma (PAC) who underwent FOLFIRINOX (5-fluorouracil/leucovorin/irinotecan/oxaliplatin) using clinical and computed tomography (CT) findings. METHODS: A total of 189 patients with PAC who received FOLFIRINOX were retrospectively included. Two reviewers assessed CT findings and resectability based on National Comprehensive Cancer Network guidelines. They determined tumor size changes according to Response Evaluation Criteria in Solid Tumors (RECIST 1...
March 13, 2024: Pancreas
https://read.qxmd.com/read/38524646/response-to-capmatinib-in-a-patient-with-neuroendocrine-carcinoma-of-the-gallbladder-origin-harboring-met-amplification
#34
JOURNAL ARTICLE
Shogo Yamamura, Masashi Kanai, Yasuhide Takeuchi, Natsuko Okita, Tomohiro Kondo, Masahiro Yoshioka, Junichi Matsubara, Shigemi Matsumoto, Manabu Muto
Neuroendocrine carcinoma (NEC) of the gallbladder origin is particularly rare, accounting for only 0.38% of primary malignancies of the gallbladder, and standard therapies are limited. The MET gene encodes the tyrosine kinase receptor, c-Met. Pathogenic variants of MET , such as MET exon 14 skipping and MET amplification, result in excessive downstream signaling that promotes tumor progression. A MET inhibitor, capmatinib, blocks signaling of c-Met and has been approved by the Food and Drug Administration for non-small cell lung cancer with MET exon 14 skipping...
April 2024: International cancer conference journal
https://read.qxmd.com/read/38524643/multidisciplinary-treatment-for-small-cell-carcinoma-of-the-bladder-a-case-report
#35
JOURNAL ARTICLE
Yoshie Mita, Jun Teishima, Akihisa Yao, Riku Uematsu, Takahiko Yoshii, Takuto Hara, Masato Fujisawa, Ichiro Nakamura
Small cell carcinoma (SCC) of the urinary bladder is a rare and highly aggressive subtype of bladder cancer. Most cases are diagnosed at advanced stages, and its therapeutic strategy remains unestablished. Here, we report a case of bladder SCC in which multidisciplinary treatment has resulted in relatively long-term survival. A 68-year-old man presented with gross hematuria. A cystoscopy revealed an invasive bladder tumor. A transurethral resection of bladder tumor (TURBT) was performed, and the pathological diagnosis was SCC...
April 2024: International cancer conference journal
https://read.qxmd.com/read/38518649/dehydrocostus-lactone-alleviates-irinotecan-induced-intestinal-mucositis-by-blocking-tlr4-md2-complex-formation
#36
JOURNAL ARTICLE
Miaomiao Sun, Honghong Zhan, Xiaoliang Long, Ali M Alsayed, Zhe Wang, Fancheng Meng, Guowei Wang, Jingxin Mao, Zhihua Liao, Min Chen
BACKGROUND: Irinotecan (CPT-11) is used as chemotherapeutic drug for treatment of colorectal cancer. However, without satisfactory treatments, its gastrointestinal toxicities such as diarrhea and intestinal inflammation severely restrained its clinical application. Roots of Aucklandia lappa Decne. are used as traditional Chinese medicine to relieve gastrointestinal dysfunction and dehydrocostus lactone (DHL) is one of its main active components. Nevertheless, the efficacy and mechanism of DHL against intestinal mucositis remains unclear...
February 3, 2024: Phytomedicine
https://read.qxmd.com/read/38517054/identification-and-characterization-of-camptothecin-tailoring-enzymes-in-nothapodytes-tomentosa
#37
JOURNAL ARTICLE
Yin Chen, Jian-Ping Huang, Yong-Jiang Wang, Meng-Ling Tu, Junheng Li, Bingyan Xu, Guoqing Peng, Jing Yang, Sheng-Xiong Huang
Camptothecin is a complex monoterpenoid indole alkaloid with remarkable antitumor activity. Given that two C-10 modified camptothecin derivatives, topotecan and irinotecan, have been approved as potent anticancer agents, there is a critical need for methods to access other aromatic ring-functionalized congeners (e.g., C-9, C-10, etc.). However, contemporary methods for chemical oxidation are generally harsh and low-yielding when applied to the camptothecin scaffold, thereby limiting the development of modified derivatives...
March 22, 2024: Journal of Integrative Plant Biology
https://read.qxmd.com/read/38510900/irinotecan-induced-transient-dysarthria-in-a-patient-with-metastatic-colorectal-cancer-a-case-report
#38
Kim Alfred E Inting, Anthony N Piano
We present a rare case of irinotecan-induced transient dysarthria in a 60-year-old female undergoing FOLFIRI (folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan) chemotherapy for metastatic colorectal cancer. In eight out of the 12 cycles, an isolated, self-limiting "lingual dysarthria" with tongue stiffness consistently occurred during infusion and resolved promptly upon completion. Cranial imaging done during the initial episode and after the completion of the chemotherapy regimen were unremarkable...
February 2024: Curēus
https://read.qxmd.com/read/38505718/protocol-of-a-phase-ii-study-investigating-the-efficacy-and-safety-of-trifluridine-tipiracil-plus-ramucirumab-as-a-third-line-or-later-treatment-for-advanced-gastric-cancer
#39
JOURNAL ARTICLE
Koki Nakanishi, Chie Tanaka, Mitsuro Kanda, Kazushi Miyata, Nozomu Machida, Mitsuru Sakai, Daisuke Kobayashi, Hitoshi Teramoto, Akiharu Ishiyama, Bin Sato, Takashi Oshima, Masaki Kajikawa, Hidenobu Matsushita, Kiyoshi Ishigure, Katsuya Yamashita, Shinichi Fujitake, Satoshi Sueoka, Takahiro Asada, Dai Shimizu, Shizuki Sugita, Yachiyo Kuwatsuka, Osamu Maeda, Satoshi Furune, Kenta Murotani, Yuichi Ando, Tomoki Ebata, Yasuhiro Kodera
In Japan, systemic chemotherapy is the standard treatment for unresectable, advanced, or recurrent gastric cancer. However, numerous patients with gastric cancer do not receive late-line treatment because of the rapid progression of gastric cancer. Additionally, late-line treatments, such as nivolumab, trifluridine tipiracil (FTD/TPI), or irinotecan, have limited effects on improving clinical symptoms and delaying the onset of symptoms associated with cancer progression. Recently, a combination of FTD/TPI and ramucirumab was reported to have a high response rate in late-line treatment; however, owing to patient selection bias and a high rate of hematologic toxicity in that previous study, this regimen may not be feasible in real-world clinical applications...
February 2024: Nagoya Journal of Medical Science
https://read.qxmd.com/read/38497131/individual-irinotecan-therapy-under-the-guidance-of-pre-treated-ugt1a1-6-genotyping-in-gastric-cancer
#40
JOURNAL ARTICLE
Huifang Lv, Caiyun Nie, Yunduan He, Beibei Chen, Yingjun Liu, Junling Zhang, Xiaobing Chen
Background: Severe delayed diarrhea and hematological toxicity limit the use of irinotecan. Uridine diphosphate glucuronosyltransferase 1A1 ( UGT1A1 ) is a critical enzyme in irinotecan metabolism. The study aims to investigate the safety and efficacy of irinotecan under the guidance of the pre-treatment UGT1A1 genotype in the second-line treatment of gastric cancer. Methods: This study involved 110 patients. Irinotecan was injected intravenously every 3 weeks, and the dose of irinotecan was determined by polymorphism of the UGT1A1 gene, which was divided into three groups (125 mg/m2 : GG type; 100 mg/m2 : GA type; 75 mg/m2 : AA type)...
2024: Technology in Cancer Research & Treatment
keyword
keyword
21455
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.